Mobility and quality of life among adults with 5q-spinal muscular atrophy: the influence of individual history

2022 ◽  
Vol 65 (2) ◽  
pp. 101552
Author(s):  
Tymothée Poitou ◽  
François Constant Boyer ◽  
Charlène Benoit ◽  
Jean-Baptiste Ferté ◽  
Charlotte Pineau ◽  
...  
2021 ◽  
Vol Volume 15 ◽  
pp. 729-739
Author(s):  
Yazed AlRuthia ◽  
Ghadah S Almuaythir ◽  
Hala H Alrasheed ◽  
Wejdan R Alsharif ◽  
Mohamad-Hani Temsah ◽  
...  

Neurology ◽  
2020 ◽  
Vol 95 (1) ◽  
pp. e1-e10 ◽  
Author(s):  
Georgina M. Chambers ◽  
Stella Nalukwago Settumba ◽  
Kate A. Carey ◽  
Anita Cairns ◽  
Manoj P. Menezes ◽  
...  

ObjectiveTo quantify the economic and health-related quality of life (HRQoL) burden incurred by households with a child affected by spinal muscular atrophy (SMA).MethodsHospital records, insurance claims, and detailed resource use questionnaires completed by caregivers were used to capture the direct and indirect costs to households of 40 children affected by SMA I, II, and III in Australia between 2016 and 2017. Prevalence costing methods were used and reported in 2017 US dollar (USD) purchasing power parity (PPP). The HRQoL for patients and primary caregivers was quantified with the youth version of the EQ-5D and CareQoL multiattribute utility instruments and Australian utility weights.ResultsThe average total annual cost of SMA per household was $143,705 USD PPP for all SMA types (SMA I $229,346, SMA II $150,909, SMA III $94,948). Direct costs accounted for 56% of total costs. The average total indirect health care costs for all SMA types were $63,145 per annum and were highest in families affected by SMA II. Loss of income and unpaid informal care made up 24.2% and 19.8% respectively, of annual SMA costs. Three of 4 (78%) caregivers stated that they experienced financial problems because of care tasks. The loss in HRQoL of children affected by SMA and caregivers was substantial, with average caregiver and patient scores of 0.708 and 0.115, respectively (reference range 0 = death and 1 = full health).ConclusionOur results demonstrate the substantial and far-ranging economic and quality of life burden on households and society of SMA and are essential to fully understanding the health benefits and cost-effectiveness associated with emerging disease-modifying therapies for SMA.


2016 ◽  
Vol 54 (5) ◽  
pp. 850-855 ◽  
Author(s):  
Esther Th Kruitwagen-Van Reenen ◽  
Renske I Wadman ◽  
Johanna Ma Visser-Meily ◽  
Leonard H. van den Berg ◽  
Carin Schröder ◽  
...  

2020 ◽  
Vol 35 (5) ◽  
pp. 322-330
Author(s):  
Meaghann S. Weaver ◽  
Rewais Hanna ◽  
Scott Hetzel ◽  
Karen Patterson ◽  
Alice Yuroff ◽  
...  

Background: Spinal muscular atrophy is an autosomal-recessive, progressive neuromuscular disease associated with extensive morbidity. Children with spinal muscular atrophy have potentially increased life spans due to improved nutrition, respiratory support, and novel pharmaceuticals. Objectives: To report on the quality of life and family experience for children with spinal muscular atrophy with attentiveness to patient- and proxy-concordance and to stratify quality of life reports by spinal muscular atrophy type and medical interventions. Methods: A prospective, crossover survey study inclusive of 58 children (26 spinal muscular atrophy type I, 23 type II, 9 type III) and their family caregivers at a free-standing Midwestern children’s hospital. Twenty-eight families completed the 25-item PedsQL 3.0 Neuromuscular Module. Forty-four participants completed the 36-item PedsQL Family Impact Module and 47 completed the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) questionnaire. Results: The PedsQL Family Impact Module demonstrated significant differences between spinal muscular atrophy types I and II in functioning domains including physical, emotional, social, and family relations ( P < .03). Child self-report and proxy report surveys demonstrated significant differences between spinal muscular atrophy types in the communication domains ( P < .003). Children self-reported their quality of life higher than proxy report of child quality of life. Gastrostomy tube ( P = .001) and ventilation support ( P = .029) impacted proxy-reported quality of life perspectives, whereas nusinersen use did not. Spinal surgery was associated with improved parental quality of life and family impact ( P < .03). Conclusions: The measurement and monitoring of quality of life for children with spinal muscular atrophy and their families represents an implementable priority for care teams.


2019 ◽  
Vol 23 (3) ◽  
pp. 347-356 ◽  
Author(s):  
Erik Landfeldt ◽  
Josefin Edström ◽  
Thomas Sejersen ◽  
Már Tulinius ◽  
Hanns Lochmüller ◽  
...  

2017 ◽  
Vol 12 (1) ◽  
Author(s):  
Julio López-Bastida ◽  
Luz María Peña-Longobardo ◽  
Isaac Aranda-Reneo ◽  
Eduardo Tizzano ◽  
Mark Sefton ◽  
...  

2020 ◽  
Author(s):  
Lisa Belter ◽  
Rosángel Cruz ◽  
Jill Jarecki

Abstract BACKGROUND Individuals and/or caregivers of individuals affected by Spinal Muscular Atrophy (SMA) completed the 2019 Cure SMA Community Update Survey, online, assessing health-related quality of life (HRQoL), loss of work productivity, and fatigue using the Health Utilities Index Questionnaire (HUI), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue SF), respectively. The purpose was to collect baseline quality of life results among individuals affected by SMA using the above Patient Reported Outcome Measures (PROMs). RESULTS Of 666 surveys completed between March and May 2019, 478 were included in this analysis, accounting for duplicates, missing data, or deaths. The breakdown across SMA type I, II and III was 25%, 47% and 28%, respectively. Responses were characterized by current functional status/milestone, with subsets for “permanent ventilation,” “non-sitters,” “sitters,” “walk with support,” and “walk alone.” WPAI and HUI respondents included affected adults and caregivers. The PROMIS Fatigue SF was completed by the primary caregiver of affected children. Overall, those affected by a less severe form of SMA and with a higher functional status reported higher HRQoL and lower work productivity and activity impairment. All affected individuals reported higher fatigue levels than the general population. CONCLUSIONS This study offers useful insights into the burden of SMA among affected individuals and their caregivers. The results provide a baseline picture of the patient and caregiver experience with SMA in a post-treatment era from which to measure year-over-year changes in quality of life scores from new therapies and improved care. The WPAI demonstrates the significant impact of work productivity among SMA populations. Aspects of the HUI seem more appropriate to certain SMA sub-populations than others. Measures from the PROMIS Fatigue SF appear to under-represent the burden of fatigue often reported by SMA individuals and caregivers; this may, perhaps be due to a lack of sensitivity in the questions associated with fatigue in the SMA affected population, when compared with other studies on this topic. Overall, these results suggest the need for SMA-specific quality of life outcome measures to fully capture clinically meaningful change in the SMA population.


Sign in / Sign up

Export Citation Format

Share Document